Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
10.54
+0.81 (8.32%)
At close: Nov 6, 2026, 4:00 PM EST
10.60
+0.06 (0.57%)
After-hours: Nov 6, 2026, 7:30 PM EST
Corvus Pharmaceuticals Employees
Corvus Pharmaceuticals had 37 employees as of December 31, 2025. The number of employees increased by 6 or 19.35% compared to the previous year. That makes Corvus Pharmaceuticals the 36,314th largest employer in the world and 4,976th in the United States.
Employees
37
Change (1Y)
6
Growth (1Y)
19.35%
Revenue / Employee
n/a
Profits / Employee
-$1,738,243
Market Cap
886.63M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 37 | 6 | 19.35% | 37 | 0 |
| Dec 31, 2024 | 31 | 3 | 10.71% | 31 | 0 |
| Dec 31, 2023 | 28 | -1 | -3.45% | 28 | 0 |
| Dec 31, 2022 | 29 | 1 | 3.57% | 29 | 0 |
| Dec 31, 2021 | 28 | -14 | -33.33% | 28 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pharming Group | 407 |
| MeiraGTx Holdings | 393 |
| Syndax Pharmaceuticals | 298 |
| Alumis | 239 |
| Monte Rosa Therapeutics | 173 |
| Prime Medicine | 146 |
| Odyssey Therapeutics | 100 |
| Inventiva | 87 |
CRVS News
- 1 day ago - Corvus Pharmaceuticals reports Q3 EPS (22c), consensus (20c) - TheFly
- 1 day ago - Corvus Pharmaceuticals Earnings Call Transcript: Q3 2026 - Transcripts
- 1 day ago - Corvus Pharmaceuticals Earnings release: Q3 2026 - Filings
- 1 day ago - Corvus Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 2 days ago - Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition - GlobeNewsWire
- 8 days ago - Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026 - GlobeNewsWire
- 8 days ago - Corvus Pharmaceuticals price target lowered to $27 from $30 at Mizuho - TheFly
- 5 weeks ago - Corvus announces initiation of Phase 1b clinical trial of soquelitinib - TheFly